Bone morphogenetic proteins in inflammation, glucose homeostasis and adipose tissue energy metabolism

Cytokine and Growth Factor Reviews

Volumn 27, Issue , 2016, Pages 105-118

  Grgurevic, Lovorka ^a   Christensen, Gitte Lund ^b   Schulz, Tim J ^c,d   Vukicevic, Slobodan ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^d GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

Author keywords

Bone morphogenetic proteins; Brown adipose tissue; Energy metabolism; Glucose homeostasis; Inflammation; Islet biology

Indexed keywords

BONE MORPHOGENETIC PROTEIN; GLUCOSE;

ADIPOCYTE; ADULTHOOD; ANEMIA; ANKYLOSING SPONDYLITIS; BROWN ADIPOSE TISSUE; ENERGY EXPENDITURE; FIBROSIS; GLUCOSE HOMEOSTASIS; HEMOCHROMATOSIS; HUMAN; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; IRON METABOLISM; MYOSITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; THERMOGENESIS; VASCULITIS; WHITE ADIPOSE TISSUE; ADIPOSE TISSUE; ANIMAL; ENERGY METABOLISM; HOMEOSTASIS; METABOLISM;

ADIPOSE TISSUE; ANIMALS; BONE MORPHOGENETIC PROTEINS; DIABETES MELLITUS, TYPE 2; ENERGY METABOLISM; GLUCOSE; HOMEOSTASIS; HUMANS; INFLAMMATION;

EID: 84957438127     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2015.12.009     Document Type: Review

References (190)

1. Nakashima M., Reddi A.H. The application of bone morphogenetic proteins to dental tissue engineering. Nat. Biotechnol. 2003, 21:1025-1032.
2. Sanchez-Duffhues G., Hiepen C., Knaus P., Ten D.P. Bone morphogenetic protein signaling in bone homeostasis. Bone 2015, 80:43-59.
3. Vukicevic S., Stavljenic A., Pecina M. Discovery and clinical applications of bone morphogenetic proteins. Eur. J. Clin. Chem. Clin. Biochem. 1995, 33:661-671.
4. Sieber C., Kopf J., Hiepen C., Knaus P. Recent advances in BMP receptor signaling. Cytokine Growth Factor Rev. 2009, 20:343-355.
5. Korchynskyi O., van Bezooijen R.L., Lowik C.W.G.M., ten Dijke P. Bone morphogenetic protein receptors and their nuclear effectors in bone formation. Bone Morphogenetic Proteins: Regeneration of Bone and Beyond 2004, 9-114. Birkauser Verlag, Basel -Boston-Berlin. S. Vukicevic, T.K. Sampath (Eds.).
6. Vukicevic S., Grgurevic L. Bone morphogenetic proteins in Inflammation. Encyclopedia of Inflammatory Diseases 2015, 1-15. Springer Verlag, Basel. M. Parnham (Ed.).
7. Bataller R., Brenner D.A. Liver fibrosis. J. Clin. Invest. 2005, 115:209-218.
8. Ramachandran P., Iredale J.P. Liver fibrosis: a bidirectional model of fibrogenesis and resolution. QJM 2012, 105:813-817.
9. Povero D., Busletta C., Novo E., di Bonzo L.V., Cannito S., Paternostro C., et al. Liver fibrosis: a dynamic and potentially reversible process. Histol. Histopathol. 2010, 25:1075-1091.
10. Zeisberg M., Hanai J., Sugimoto H., Mammoto T., Charytan D., Strutz F., et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat. Med. 2003, 9:964-968.
11. Bi J., Ge S. Potential roles of BMP9 in liver fibrosis. Int. J. Mol. Sci. 2014, 15:20656-20667.
12. Sugimoto H., Yang C., LeBleu V.S., Soubasakos M.A., Giraldo M., Zeisberg M., et al. BMP-7 functions as a novel hormone to facilitate liver regeneration. FASEB J. 2007, 21:256-264.
13. Cao H., Shu X., Chen L.B., Zhang K., Xu Q.H., Li G. The relationship of expression of BMP-7 in the liver and hepatic inflammation and fibrosis in patients with chronic HBV infection. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2010, 24:101-103.
14. Hao Z.M., Cai M., Lv Y.F., Huang Y.H., Li H.H. Oral administration of recombinant adeno-associated virus-mediated bone morphogenetic protein-7 suppresses CCl(4)-induced hepatic fibrosis in mice. Mol. Ther. 2012, 20:2043-2051.
15. Li B., Shao Q., Ji D., Li F., Chen G. Mesenchymal stem cells mitigate cirrhosis through BMP7. Cell Physiol. Biochem. 2015, 35:433-440.
16. Xu C.P., Ji W.M., van den Brink G.R., Peppelenbosch M.P. Bone morphogenetic protein-2 is a negative regulator of hepatocyte proliferation downregulated in the regenerating liver. World J. Gastroenterol. 2006, 12:7621-7625.
17. Gao X., Cao Y., Yang W., Duan C., Aronson J.F., Rastellini C., et al. BMP2 inhibits TGF-beta-induced pancreatic stellate cell activation and extracellular matrix formation. Am. J. Physiol. Gastrointest. Liver Physiol. 2013, 304:G804-G813.
18. Takabayashi H., Shinohara M., Mao M., Phaosawasdi P., El-Zaatari M., Zhang M., et al. Anti-inflammatory activity of bone morphogenetic protein signaling pathways in stomachs of mice. Gastroenterology 2014, 147:396-406.
19. Jiang M., Ku W.Y., Zhou Z., Dellon E.S., Falk G.W., Nakagawa H., et al. BMP-driven NRF2 activation in esophageal basal cell differentiation and eosinophilic esophagitis. J. Clin. Invest. 2015, 125:1557-1568.
20. Batts L.E., Polk D.B., Dubois R.N., Kulessa H. Bmp signaling is required for intestinal growth and morphogenesis. Dev. Dyn. 2006, 235:1563-1570.
21. Smith P.J., Levine A.P., Dunne J., Guilhamon P., Turmaine M., Sewell G.W., et al. Mucosal transcriptomics implicates under expression of BRINP3 in the pathogenesis of ulcerative colitis. Inflamm. Bowel Dis. 2014, 20:1802-1812.
22. Fiocchi C. Early and late inflammatory bowel disease: why and how are they different?. Curr. Opin. Gastroenterol. 2011, 27:317-320.
23. Maric I., Poljak L., Zoricic S., Bobinac D., Bosukonda D., Sampath K.T., et al. Bone morphogenetic protein-7 reduces the severity of colon tissue damage and accelerates the healing of inflammatory bowel disease in rats. J. Cell Physiol. 2003, 196:258-264.
24. Monteleone G., Pallone F., MacDonald T.T. Smad7 in TGF-beta-mediated negative regulation of gut inflammation. Trends Immunol. 2004, 25:513-517.
25. Latella G., Vetuschi A., Sferra R., Zanninelli G., D'Angelo A., Catitti V., et al. Smad3 loss confers resistance to the development of trinitrobenzene sulfonic acid-induced colorectal fibrosis. Eur. J. Clin. Invest. 2009, 39:145-156.
26. Hao Z., Yang X., Lv Y., Li S., Purbey B.K., Su H. Intracolonically administered adeno-associated virus-bone morphogenetic protein-7 ameliorates dextran sulphate sodium-induced acute colitis in rats. J. Gene Med. 2012, 14:482-490.
27. Hadad A. SMAD7: un oligonucletido antisentido oral para el tratamiento de la enfermedad de Crohn. Enfermedad Inflamatoria Intestinal al D + şa 2015, 14:39-40.
28. Monteleone G., Neurath M.F., Ardizzone S., Di S.A., Fantini M.C., Castiglione F., et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. N. Engl. J. Med. 2015, 372:1104-1113.
29. Hentze M.W., Muckenthaler M.U., Galy B., Camaschella C. Two to tango: regulation of mammalian iron metabolism. Cell 2010, 142:24-38.
30. Wang L., Trebicka E., Fu Y., Ellenbogen S., Hong C.C., Babitt J.L., et al. The bone morphogenetic protein-hepcidin axis as a therapeutic target in inflammatory bowel disease. Inflamm. Bowel Dis. 2012, 18:112-119.
31. Gao J., Chen J., Kramer M., Tsukamoto H., Zhang A.S., Enns C.A. Interaction of the hereditary hemochromatosis protein HFE with transferrin receptor 2 is required for transferrin-induced hepcidin expression. Cell Metab. 2009, 9:217-227.
32. Bagu E.T., Layoun A., Calve A., Santos M.M. Friend of GATA and GATA-6 modulate the transcriptional up-regulation of hepcidin in hepatocytes during inflammation. Biometals 2013, 26:1051-1065.
33. Pauk M., Grgurevic L., Brkljacic J., Kufner V., Bordukalo-Niksic T., Grabusic K., et al. Exogenous BMP7 corrects the plasma iron overload and bone loss in Bmp6-/- mice. Int. Orthop. 2014, 39:161-172.
34. Andriopoulos B., Corradini E., Xia Y., Faasse S.A., Chen S., Grgurevic L., et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat. Genet. 2009, 41:482-487.
35. Shanmugam N.K., Ellenbogen S., Trebicka E., Wang L., Mukhopadhyay S., Lacy-Hulbert A., et al. Tumor necrosis factor alpha inhibits expression of the iron regulating hormone hepcidin in murine models of innate colitis. PLoS One 2012, 7:e38136.
36. Park M.C., Chung S.J., Park Y.B., Lee S.K. Relationship of angiogenic factors to disease activity and radiographic damage in rheumatoid arthritis. Clin. Exp. Rheumatol. 2008, 26:881-886.
37. Biver E., Hardouin P., Caverzasio J. The bone morphogenic proteins pathways in bone and joint diseases: translational perspectives from physiopathology to therapeutic targets. Cytokine Growth Factor Rev. 2013, 24:69-81.
38. Grcevic D., Jajic Z., Kovacic N., Lukic I.K., Velagic V., Grubisic F., et al. Peripheral blood expression profiles of bone morphogenetic proteins, tumor necrosis factor-superfamily molecules, and transcription factor Runx2 could be used as markers of the form of arthritis, disease activity, and therapeutic responsiveness. J. Rheumatol. 2010, 37:246-256.
39. Drexler S.K., Kong P.L., Wales J., Foxwell B.M. Cell signalling in macrophages, the principal innate immune effector cells of rheumatoid arthritis. Arthritis. Res. Ther. 2008, 10:216.
40. Lories R.J., Derese I., Ceuppens J.L., Luyten F.P. Bone morphogenetic proteins 2 and 6, expressed in arthritic synovium, are regulated by proinflammatory cytokines and differentially modulate fibroblast-like synoviocyte apoptosis. Arthritis. Rheum. 2003, 48:2807-2818.
41. Takahashi T., Muneta T., Tsuji K., Sekiya I. BMP-7 inhibits cartilage degeneration through suppression of inflammation in rat zymosan-induced arthritis. Cell Tissue Res. 2011, 344:321-332.
42. Bramlage C.P., Haupl T., Kaps C., Ungethum U., Krenn V., Pruss A., et al. Decrease in expression of bone morphogenetic proteins 4 and 5 in synovial tissue of patients with osteoarthritis and rheumatoid arthritis. Arthritis. Res. Ther. 2006, 8:R58.
43. Guo X., Wang X.F. Signaling cross-talk between TGF-beta/BMP and other pathways. Cell Res. 2009, 19:71-88.
44. Grazio S., Razdorov G., Erjavec I., Grubisic F., Kusic Z., Punda M., et al. Differential expression of proteins with heparin affinity in patients with rheumatoid and psoriatic arthritis: a preliminary study. Clin. Exp. Rheumatol. 2013, 31:665-671.
45. Verschueren P.C., Lories R.J., Daans M., Theate I., Durez P., Westhovens R., et al. Detection, identification and in vivo treatment responsiveness of bone morphogenetic protein (BMP)-activated cell populations in the synovium of patients with rheumatoid arthritis. Ann. Rheum. Dis. 2009, 68:117-123.
46. Machado P., Landewe R., Braun J., Hermann K.G., Baker D., van der Heijde D. Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. Ann. Rheum. Dis. 2010, 69:1465-1470.
47. Carter S., Lories R.J. Osteoporosis: a paradox in ankylosing spondylitis. Curr. Osteoporos. Rep. 2011, 9:112-115.
48. Chen M.H., Chen H.A., Chen W.S., Chen M.H., Tsai C.Y., Chou C.T. Upregulation of BMP-2 expression in peripheral blood mononuclear cells by proinflammatory cytokines and radiographic progression in ankylosing spondylitis. Mod. Rheumatol. 2015, 1-6.
49. Chubinskaya S., Hurtig M., Rueger D.C. OP-1/BMP-7 in cartilage repair. Int. Orthop. 2007, 31:773-781.
50. Chubinskaya S., Segalite D., Pikovsky D., Hakimiyan A.A., Rueger D.C. Effects induced by BMPS in cultures of human articular chondrocytes: comparative studies. Growth Factors 2008, 26:275-283.
51. Daans M., Lories R.J., Luyten F.P. Dynamic activation of bone morphogenetic protein signaling in collagen-induced arthritis supports their role in joint homeostasis and disease. Arthritis Res. Ther. 2008, 10:R115.
52. Korkosz M., Gasowski J., Leszczynski P., Pawlak-Bus K., Jeka S., Siedlar M., et al. Effect of tumour necrosis factor-alpha inhibitor on serum level of dickkopf-1 protein and bone morphogenetic protein-7 in ankylosing spondylitis patients with high disease activity. Scand. J. Rheumatol. 2014, 43:43-48.
53. Tsui F.W., Tsui H.W., Las H.F., Pritzker K.P., Inman R.D. Serum levels of novel noggin and sclerostin-immune complexes are elevated in ankylosing spondylitis. Ann. Rheum. Dis. 2014, 73:1873-1879.
54. Hatsell S.J., Idone V., Wolken D.M., Huang L., Kim H.J., Wang L., et al. ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A. Sci. Transl. Med. 2015, 7:7:303ra137.
55. Kaplan F.S., Pignolo R.J., Shore E.M. From mysteries to medicines: drug development for fibrodysplasia ossificans progressive. Expert Opin. Orphan Drugs 2013, 1:637-649.
56. White A.P., Vaccaro A.R., Hall J.A., Whang P.G., Friel B.C., McKee M.D. Clinical applications of BMP-7/OP-1 in fractures, nonunions and spinal fusion. Int. Orthop. 2007, 31:735-741.
57. Moghaddam A., Elleser C., Biglari B., Wentzensen A., Zimmermann G. Clinical application of BMP 7 in long bone non-unions. Arch. Orthop Trauma Surg. 2010, 130:71-76.
58. Vukicevic S., Oppermann H., Verbanac D., Jankolija M., Popek I., Curak J., et al. The clinical use of bone morphogenetic proteins revisited: a novel biocompatible carrier device OSTEOGROW for bone healing. Int. Orthop. 2014, 38:635-647.
59. Zara J.N., Siu R.K., Zhang X., Shen J., Ngo R., Lee M., et al. High doses of bone morphogenetic protein 2 induce structurally abnormal bone and inflammation in vivo. Tissue Eng. Part A 2011, 17:1389-1399.
60. Sagi H.C., Jordan C.J., Barei D.P., Serrano-Riera R., Steverson B. Indomethacin prophylaxis for heterotopic ossification after acetabular fracture surgery increases the risk for nonunion of the posterior wall. J. Orthop. Trauma 2014, 28:377-383.
61. Lee K.B., Taghavi C.E., Murray S.S., Song K.J., Keorochana G., Wang J.C. BMP induced inflammation: a comparison of rhBMP-7 and rhBMP-2. J. Orthop. Res. 2012, 30:1985-1994.
62. Dumic-Cule I., Brkljacic J., Rogic D., Bordukalo-Niksic T., Tikvica Luetic A., Draca N., et al. Systemically available bone morphogenetic protein 2 and 7 affect bone metabolism. Int. Orthop. 2014, 38(9):1979-1985. 10.1007/s00264-014-2425-8.
63. Peric M., Dumic-Cule I., Grcevic D., Matijasic M., Verbanac D., Grgurevic L., et al. The rational use of animal models in the evaluation of novel bone regenerative therapies. Bone 2015, 70:70-86.
64. Ross R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 1999, 340:115-126.
65. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation 2002, 105:1135-1143.
66. Yao Y., Bennett B.J., Wang X., Rosenfeld M.E., Giachelli C., Lusis A.J., et al. Inhibition of bone morphogenetic proteins protects against atherosclerosis and vascular calcification. Circ. Res. 2010, 107:485-494.
67. Helbing T., Rothweiler R., Ketterer E., Goetz L., Heinke J., Grundmann S., et al. BMP activity controlled by BMPER regulates the proinflammatory phenotype of endothelium. Blood 2011, 118:5040-5049.
68. Buendia P., Montes de O.A., Madueno J.A., Merino A., Martin-Malo A., Aljama P., et al. Endothelial microparticles mediate inflammation-induced vascular calcification. FASEB J. 2015, 29:173-181.
69. Miriyala S., Gongora Nieto M.C., Mingone C., Smith D., Dikalov S., Harrison D.G., et al. Bone morphogenic protein-4 induces hypertension in mice: role of noggin, vascular NADPH oxidases, and impaired vasorelaxation. Circulation 2006, 113:2818-2825.
70. Pardali E., ten Dijke P. TGFbeta signaling and cardiovascular diseases. Int. J. Biol. Sci. 2012, 8:195-213.
71. Nakagawa Y., Ikeda K., Akakabe Y., Koide M., Uraoka M., Yutaka K.T., et al. Paracrine osteogenic signals via bone morphogenetic protein-2 accelerate the atherosclerotic intimal calcification in vivo. Arterioscler. Thromb. Vasc. Biol. 2010, 30:1908-1915.
72. Davies R.J., Holmes A.M., Deighton J., Long L., Yang X., Barker L., et al. BMP type II receptor deficiency confers resistance to growth inhibition by TGF-beta in pulmonary artery smooth muscle cells: role of proinflammatory cytokines. Am. J. Physiol. Lung Cell. Mol. Physiol. 2012, 302:L604-L615.
73. Simic T. Anti-inflammatory and anti-atherogenic role of BMP receptor II in atherosclerosis. Future Cardiol. 2013, 9:619-622.
74. Nurgazieva D., Mickley A., Moganti K., Ming W., Ovsyi I., Popova A., et al. TGF-beta1, but not bone morphogenetic proteins, activates Smad1/5 pathway in primary human macrophages and induces expression of proatherogenic genes. J. Immunol. 2015, 194:709-718.
75. Rocher C., Singla R., Singal P.K., Parthasarathy S., Singla D.K. Bone morphogenetic protein 7 polarizes THP-1 cells into M2 macrophages. Can. J. Physiol. Pharmacol. 2012, 90:947-951.
76. Koga M., Engberding N., Dikalova A.E., Chang K.H., Seidel-Rogol B., Long J.S., et al. The bone morphogenic protein inhibitor, noggin, reduces glycemia and vascular inflammation in db/db mice. Am. J. Physiol. Heart Circ. Physiol. 2013, 305:H747-H755.
77. Danaei G., Finucane M.M., Lu Y., Singh G.M., Cowan M.J., Paciorek C.J., et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011, 378:31-40.
78. Lionetti L., Mollica M.P., Lombardi A., Cavaliere G., Gifuni G., Barletta A. From chronic overnutrition to insulin resistance: the role of fat-storing capacity and inflammation. Nutr. Metab. Cardiovasc. Dis. 2009, 19:146-152.
79. Donath M.Y., Shoelson S.E. Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol. 2011, 11:98-107.
80. Weir G.C., Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes 2004, 53(Suppl. 3):S16-S21.
81. Butler A.E., Janson J., Bonner-Weir S., Ritzel R., Rizza R.A., Butler P.C. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003, 52:102-110.
82. Ahnfelt-Ronne J., Ravassard P., Pardanaud-Glavieux C., Scharfmann R., Serup P. Mesenchymal bone morphogenetic protein signaling is required for normal pancreas development. Diabetes 2010, 59:1948-1956.
83. Chung W.S., Andersson O., Row R., Kimelman D., Stainier D.Y. Suppression of Alk8-mediated Bmp signaling cell-autonomously induces pancreatic beta-cells in zebrafish. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:1142-1147.
84. Wandzioch E., Zaret K.S. Dynamic signaling network for the specification of embryonic pancreas and liver progenitors. Science 2009, 324:1707-1710.
85. Dichmann D.S., Miller C.P., Jensen J., Scott Heller R., Serup P. Expression and misexpression of members of the FGF and TGFbeta families of growth factors in the developing mouse pancreas. Dev. Dyn. 2003, 226:663-674.
86. Gu G., Dubauskaite J., Melton D.A. Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors. Development 2002, 129:2447-2457.
87. Collombat P., Hecksher-Sorensen J., Serup P., Mansouri A. Specifying pancreatic endocrine cell fates. Mech. Dev. 2006, 123:501-512.
88. Gittes G.K. Developmental biology of the pancreas: a comprehensive review. Dev. Biol. 2009, 326:4-35.
89. Bardeesy N., Cheng K.H., Berger J.H., Chu G.C., Pahler J., Olson P., et al. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev. 2006, 20:3130-3146.
90. Bruun C., Christensen G.L., Jacobsen M.L., Kanstrup M.B., Jensen P.R., Fjordvang H., et al. Inhibition of beta cell growth and function by bone morphogenetic proteins. Diabetologia 2014, 57:2546-2554.
91. Ghil S.H., Jeon Y.J., Suh-Kim H. Inhibition of BETA2/NeuroD by Id2. Exp. Mol. Med. 2002, 34:367-373.
92. Gu C., Stein G.H., Pan N., Goebbels S., Hornberg H., Nave K.A., et al. Pancreatic beta cells require NeuroD to achieve and maintain functional maturity. Cell Metab. 2010, 11:298-310.
93. Russ H.A., Parent A.V., Ringler J.J., Hennings T.G., Nair G.G., Shveygert M., et al. Controlled induction of human pancreatic progenitors produces functional beta-like cells in vitro. EMBO J. 2015, 34:1759-1772.
94. Pagliuca F.W., Millman J.R., Gurtler M., Segel M., Van D.A., Ryu J.H., et al. Generation of functional human pancreatic beta cells in vitro. Cell 2014, 159:428-439.
95. Rezania A., Bruin J.E., Arora P., Rubin A., Batushansky I., Asadi A., et al. Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. Nat. Biotechnol. 2014, 32:1121-1133.
96. Goulley J., Dahl U., Baeza N., Mishina Y., Edlund H. BMP4-BMPR1A signaling in beta cells is required for and augments glucose-stimulated insulin secretion. Cell Metab. 2007, 5:207-219.
97. Benner C., van der Meulen T., Caceres E., Tigyi K., Donaldson C.J., Huising M.O. The transcriptional landscape of mouse beta cells compared to human beta cells reveals notable species differences in long non-coding RNA and protein-coding gene expression. BMC Genomics 2014, 15:620.
98. Kjorholt C., Akerfeldt M.C., Biden T.J., Laybutt D.R. Chronic hyperglycemia, independent of plasma lipid levels, is sufficient for the loss of beta-cell differentiation and secretory function in the db/db mouse model of diabetes. Diabetes 2005, 54:2755-2763.
99. Bensellam M., Montgomery M.K., Luzuriaga J., Chan J.Y., Laybutt D.R. Inhibitor of differentiation proteins protect against oxidative stress by regulating the antioxidant-mitochondrial response in mouse beta cells. Diabetologia 2015, 58:758-770.
100. Fukui N., Zhu Y., Maloney W.J., Clohisy J., Sandell L.J. Stimulation of BMP-2 expression by pro-inflammatory cytokines IL-1 and TNF-alpha in normal and osteoarthritic chondrocytes. J. Bone Joint Surg. Am. 2003, 85-A(Suppl. 3):59-66.
101. Fowler M.J., Neff M.S., Borghaei R.C., Pease E.A., Mochan E., Thornton R.D. Induction of bone morphogenetic protein-2 by interleukin-1 in human fibroblasts. Biochem. Biophys. Res. Commun. 1998, 248:450-453.
102. Richardson S.J., Willcox A., Bone A.J., Foulis A.K., Morgan N.G. Islet-associated macrophages in type 2 diabetes. Diabetologia 2009, 52:1686-1688.
103. Willcox A., Richardson S.J., Bone A.J., Foulis A.K., Morgan N.G. Analysis of islet inflammation in human type 1 diabetes. Clin. Exp. Immunol. 2009, 155:173-181.
104. Boni-Schnetzler M., Thorne J., Parnaud G., Marselli L., Ehses J.A., Kerr-Conte J., et al. Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta-cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation. J. Clin. Endocrinol. Metab. 2008, 93:4065-4074.
105. Boni-Schnetzler M., Boller S., Debray S., Bouzakri K., Meier D.T., Prazak R., et al. Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I. Endocrinology 2009, 150:5218-5229.
106. Eizirik D.L., Sammeth M., Bouckenooghe T., Bottu G., Sisino G., Igoillo-Esteve M., et al. The human pancreatic islet transcriptome: expression of candidate genes for type 1 diabetes and the impact of pro-inflammatory cytokines. PLoS Genet. 2012, 8:e1002552.
107. Ibarra U.A., Friberg J., Christensen D.P., Lund C.G., Billestrup N. Inflammatory cytokines stimulate bone morphogenetic protein-2 expression and release from pancreatic beta cells. J. Interferon Cytokine Res. 2015, [Epub ahead of print].
108. Busch A.K., Cordery D., Denyer G.S., Biden T.J. Expression profiling of palmitate- and oleate-regulated genes provides novel insights into the effects of chronic lipid exposure on pancreatic beta-cell function. Diabetes 2002, 51:977-987.
109. Keller M.P., Choi Y., Wang P., Davis D.B., Rabaglia M.E., Oler A.T., et al. A gene expression network model of type 2 diabetes links cell cycle regulation in islets with diabetes susceptibility. Genome Res. 2008, 18:706-716.
110. Fadista J., Vikman P., Laakso E.O., Mollet I.G., Esguerra J.L., Taneera J., et al. Global genomic and transcriptomic analysis of human pancreatic islets reveals novel genes influencing glucose metabolism. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:13924-13929.
111. Bonner C., Farrelly A.M., Concannon C.G., Dussmann H., Baquie M., Virard I., et al. Bone morphogenetic protein 3 controls insulin gene expression and is down-regulated in INS-1 cells inducibly expressing a hepatocyte nuclear factor 1A-maturity-onset diabetes of the young mutation. J. Biol. Chem. 2011, 286:25719-25728.
112. Christensen G.L., Jacobsen M.L., Wendt A., Mollet I.G., Friberg J., Frederiksen K.S., et al. Bone morphogenetic protein 4 inhibits insulin secretion from rodent beta cells through regulation of calbindin1 expression and reduced voltage-dependent calcium currents. Diabetologia 2015, 58:1282-1290.
113. Hussein K.A., Choksi K., Akeel S., Ahmad S., Megyerdi S., El-Sherbiny M., et al. Bone morphogenetic protein 2: a potential new player in the pathogenesis of diabetic retinopathy. Exp. Eye Res. 2014, 125:79-88.
114. Koga M., Yamauchi A., Kanaoka Y., Jige R., Tsukamoto A., Teshima N., et al. BMP4 is increased in the aortas of diabetic ApoE knockout mice and enhances uptake of oxidized low density lipoprotein into peritoneal macrophages. J. Inflamm. (Lond.) 2013, 10:32.
115. Tominaga T., Abe H., Ueda O., Goto C., Nakahara K., Murakami T., et al. Activation of bone morphogenetic protein 4 signaling leads to glomerulosclerosis that mimics diabetic nephropathy. J. Biol. Chem. 2011, 286:20109-20116.
116. Scott G.J., Ray M.K., Ward T., McCann K., Peddada S., Jiang F.X., et al. Abnormal glucose metabolism in heterozygous mutant mice for a type I receptor required for BMP signaling. Genesis 2009, 47:385-391.
117. Henley K.D., Gooding K.A., Economides A.N., Gannon M. Inactivation of the dual Bmp/Wnt inhibitor Sostdc1 enhances pancreatic islet function. Am. J. Physiol. Endocrinol. Metab. 2012, 303:E752-E761.
118. Chen C., Grzegorzewski K.J., Barash S., Zhao Q., Schneider H., Wang Q., et al. An integrated functional genomics screening program reveals a role for BMP-9 in glucose homeostasis. Nat. Biotechnol. 2003, 21:294-301.
119. Akerfeldt M.C., Laybutt D.R. Inhibition of Id1 augments insulin secretion and protects against high-fat diet-induced glucose intolerance. Diabetes 2011, 60:2506-2514.
120. Satyanarayana A., Klarmann K.D., Gavrilova O., Keller J.R. Ablation of the transcriptional regulator Id1 enhances energy expenditure, increases insulin sensitivity, and protects against age and diet induced insulin resistance, and hepatosteatosis. FASEB J. 2012, 26:309-323.
121. Klein D., Alvarez-Cubela S., Lanzoni G., Vargas N., Prabakar K.R., Boulina M., et al. BMP-7 induces adult human pancreatic exocrine-to-endocrine conversion. Diabetes 2015, 64(12):4123-4134. 10.2337/db15-0688.
122. Rosen E.D., Spiegelman B.M. What we talk about when we talk about fat. Cell 2014, 156:20-44.
123. Cannon B., Nedergaard J. Brown adipose tissue: function and physiological significance. Physiol. Rev. 2004, 84:277-359.
124. Klingenberg M., Huang S.G. Structure and function of the uncoupling protein from brown adipose tissue. Biochim. Biophys. Acta 1999, 1415:271-296.
125. Ricquier D., Mory G. Factors affecting brown adipose tissue activity in animals and man. Clin. Endocrinol. Metab. 1984, 13:501-520.
126. Cypess A.M., Lehman S., Williams G., Tal I., Rodman D., Goldfine A.B., et al. Identification and importance of brown adipose tissue in adult humans. N. Engl. J. Med. 2009, 360:1509-1517.
127. Nedergaard J., Bengtsson T., Cannon B. Unexpected evidence for active brown adipose tissue in adult humans. Am. J. Physiol. Endocrinol. Metab. 2007, 293:E444-E452.
128. Saito M., Okamatsu-Ogura Y., Matsushita M., Watanabe K., Yoneshiro T., Nio-Kobayashi J., et al. High incidence of metabolically active brown adipose tissue in healthy adult humans: effects of cold exposure and adiposity. Diabetes 2009, 58:1526-1531.
129. van Marken Lichtenbelt W.D., Vanhommerig J.W., Smulders N.M., Drossaerts J.M., Kemerink G.J., Bouvy N.D., et al. Cold-activated brown adipose tissue in healthy men. N. Engl. J. Med. 2009, 360:1500-1508.
130. Virtanen K.A., Lidell M.E., Orava J., Heglind M., Westergren R., Niemi T., et al. Functional brown adipose tissue in healthy adults. N. Engl. J. Med. 2009, 360:1518-1525.
131. Zingaretti M.C., Crosta F., Vitali A., Guerrieri M., Frontini A., Cannon B., et al. The presence of UCP1 demonstrates that metabolically active adipose tissue in the neck of adult humans truly represents brown adipose tissue. FASEB J. 2009, 23:3113-3120.
132. Yoneshiro T., Aita S., Matsushita M., Kayahara T., Kameya T., Kawai Y., et al. Recruited brown adipose tissue as an antiobesity agent in humans. J. Clin. Invest. 2013, 123:3404-3408.
133. Yoneshiro T., Ogawa T., Okamoto N., Matsushita M., Aita S., Kameya T., et al. Impact of UCP1 and beta3AR gene polymorphisms on age-related changes in brown adipose tissue and adiposity in humans. Int. J. Obes. (Lond.) 2013, 37:993-998.
134. Bakker L.E., Boon M.R., van der Linden R.A., Arias-Bouda L.P., van Klinken J.B., Smit F., et al. Brown adipose tissue volume in healthy lean south Asian adults compared with white Caucasians: a prospective, case-controlled observational study. Lancet Diab. Endocrinol. 2014, 2:210-217.
135. Chondronikola M., Volpi E., Borsheim E., Porter C., Annamalai P., Enerback S., et al. Brown adipose tissue improves whole-body glucose homeostasis and insulin sensitivity in humans. Diabetes 2014, 63:4089-4099.
136. Stanford K.I., Middelbeek R.J., Townsend K.L., An D., Nygaard E.B., Hitchcox K.M., et al. Brown adipose tissue regulates glucose homeostasis and insulin sensitivity. J. Clin. Invest. 2013, 123:215-223.
137. Bartelt A., Bruns O.T., Reimer R., Hohenberg H., Ittrich H., Peldschus K., et al. Brown adipose tissue activity controls triglyceride clearance. Nat. Med. 2011, 17:200-205.
138. Cypess A.M., White A.P., Vernochet C., Schulz T.J., Xue R., Sass C.A., et al. Anatomical localization, gene expression profiling and functional characterization of adult human neck brown fat. Nat. Med. 2013, 19:635-639.
139. Lidell M.E., Betz M.J., Dahlqvist L.O., Heglind M., Elander L., Slawik M., et al. Evidence for two types of brown adipose tissue in humans. Nat. Med. 2013, 19:631-634.
140. Nedergaard J., Cannon B. The browning of white adipose tissue: some burning issues. Cell Metab. 2014, 20:396-407.
141. Petrovic N., Walden T.B., Shabalina I.G., Timmons J.A., Cannon B., Nedergaard J. Chronic peroxisome proliferator-activated receptor gamma (PPARgamma) activation of epididymally derived white adipocyte cultures reveals a population of thermogenically competent, UCP1-containing adipocytes molecularly distinct from classic brown adipocytes. J. Biol. Chem. 2010, 285:7153-7164.
142. Wu J., Bostrom P., Sparks L.M., Ye L., Choi J.H., Giang A.H., et al. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. Cell 2012, 150:366-376.
143. Himms-Hagen J., Melnyk A., Zingaretti M.C., Ceresi E., Barbatelli G., Cinti S. Multilocular fat cells in WAT of CL-316243-treated rats derive directly from white adipocytes. Am. J. Physiol. Cell Physiol. 2000, 279:C670-C681.
144. Lee Y.H., Petkova A.P., Mottillo E.P., Granneman J.G. In vivo identification of bipotential adipocyte progenitors recruited by beta3-adrenoceptor activation and high-fat feeding. Cell Metab. 2012, 15:480-491.
145. Wang Q.A., Tao C., Gupta R.K., Scherer P.E. Tracking adipogenesis during white adipose tissue development, expansion and regeneration. Nat. Med. 2013, 19:1338-1344.
146. Wang W., Kissig M., Rajakumari S., Huang L., Lim H.W., Won K.J., et al. Ebf2 is a selective marker of brown and beige adipogenic precursor cells. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:14466-14471.
147. Xue R., Lynes M.D., Dreyfuss J.M., Shamsi F., Schulz T.J., Zhang H., et al. Clonal analyses and gene profiling identify genetic biomarkers of the thermogenic potential of human brown and white preadipocytes. Nat. Med. 2015, 21:760-768.
148. Lepper C., Fan C.M. Inducible lineage tracing of Pax7-descendant cells reveals embryonic origin of adult satellite cells. Genesis 2010, 48:424-436.
149. Seale P., Bjork B., Yang W., Kajimura S., Chin S., Kuang S., et al. PRDM16 controls a brown fat/skeletal muscle switch. Nature 2008, 454:961-967.
150. Sanchez-Gurmaches J., Guertin D.A. Adipocytes arise from multiple lineages that are heterogeneously and dynamically distributed. Nat. Commun. 2014, 5:4099.
151. Otto T.C., Lane M.D. Adipose development: from stem cell to adipocyte. Crit. Rev. Biochem. Mol. Biol 2005, 40:229-242.
152. Schulz T.J., Tseng Y.H. Brown adipose tissue: development, metabolism and beyond. Biochem. J. 2013, 453:167-178.
153. Tseng Y.H., Kokkotou E., Schulz T.J., Huang T.L., Winnay J.N., Taniguchi C.M., et al. New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditure. Nature 2008, 454:1000-1004.
154. Schulz T.J., Huang T.L., Tran T.T., Zhang H., Townsend K.L., Shadrach J.L., et al. Identification of inducible brown adipocyte progenitors residing in skeletal muscle and white fat. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:143-148.
155. Elsen M., Raschke S., Tennagels N., Schwahn U., Jelenik T., Roden M., et al. BMP4 and BMP7 induce the white-to-brown transition of primary human adipose stem cells. Am. J. Physiol. Cell Physiol. 2014, 306:C431-C440.
156. Gustafson B., Hammarstedt A., Hedjazifar S., Hoffmann J.M., Svensson P.A., Grimsby J., et al. BMP4 and BMP antagonists regulate human white and beige adipogenesis. Diabetes 2015, 64:1670-1681.
157. Schulz T.J., Huang P., Huang T.L., Xue R., McDougall L.E., Townsend K.L., et al. Brown-fat paucity due to impaired BMP signalling induces compensatory browning of white fat. Nature 2013, 495:379-383.
158. Taha M.F., Valojerdi M.R., Mowla S.J. Effect of bone morphogenetic protein-4 (BMP-4) on adipocyte differentiation from mouse embryonic stem cells. Anat. Histol. Embryol. 2006, 35:271-278.
159. El-Magd M.A., Allen S., McGonnell I., Otto A., Patel K. Bmp4 regulates chick Ebf2 and Ebf3 gene expression in somite development. Dev. Growth Differ. 2013, 55:710-722.
160. Warner D.R., Horn K.H., Mudd L., Webb C.L., Greene R.M., Pisano M.M. PRDM16/MEL1: a novel Smad binding protein expressed in murine embryonic orofacial tissue. Biochim. Biophys. Acta 2007, 1773:814-820.
161. Gupta R.K., Arany Z., Seale P., Mepani R.J., Ye L., Conroe H.M., et al. Transcriptional control of preadipocyte determination by Zfp423. Nature 2010, 464:619-623.
162. Gupta R.K., Mepani R.J., Kleiner S., Lo J.C., Khandekar M.J., Cohen P., et al. Zfp423 expression identifies committed preadipocytes and localizes to adipose endothelial and perivascular cells. Cell Metab. 2012, 15:230-239.
163. Schulz T.J., Tseng Y.H. Emerging role of bone morphogenetic proteins in adipogenesis and energy metabolism. Cytokine Growth Factor Rev. 2009, 20:523-531.
164. Zamani N., Brown C.W. Emerging roles for the transforming growth factor-(beta) superfamily in regulating adiposity and energy expenditure. Endocr. Rev. 2011, 32:387-403.
165. Ahrens M., Ankenbauer T., Schroder D., Hollnagel A., Mayer H., Gross G. Expression of human bone morphogenetic proteins-2 or -4 in murine mesenchymal progenitor C3H10T1/2 cells induces differentiation into distinct mesenchymal cell lineages. DNA Cell Biol. 1993, 12:871-880.
166. Chen T.L., Shen W.J., Kraemer F.B. Human BMP-7/OP-1 induces the growth and differentiation of adipocytes and osteoblasts in bone marrow stromal cell cultures. J. Cell Biochem. 2001, 82:187-199.
167. Kang Q., Song W.X., Luo Q., Tang N., Luo J., Luo X., et al. A comprehensive analysis of the dual roles of BMPs in regulating adipogenic and osteogenic differentiation of mesenchymal progenitor cells. Stem Cells Dev. 2009, 18:545-558.
168. Chen D., Ji X., Harris M.A., Feng J.Q., Karsenty G., Celeste A.J., et al. Differential roles for bone morphogenetic protein (BMP) receptor type IB and IA in differentiation and specification of mesenchymal precursor cells to osteoblast and adipocyte lineages. J. Cell Biol. 1998, 142:295-305.
169. Bowers R.R., Kim J.W., Otto T.C., Lane M.D. Stable stem cell commitment to the adipocyte lineage by inhibition of DNA methylation: role of the BMP-4 gene. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:13022-13027.
170. Tang Q.Q., Otto T.C., Lane M.D. Commitment of C3H10T1/2 pluripotent stem cells to the adipocyte lineage. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:9607-9611.
171. Puigserver P., Wu Z., Park C.W., Graves R., Wright M., Spiegelman B.M. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 1998, 92:829-839.
172. Nohe A., Keating E., Knaus P., Petersen N.O. Signal transduction of bone morphogenetic protein receptors. Cell. Signal. 2004, 16:291-299.
173. Akimoto T., Pohnert S.C., Li P., Zhang M., Gumbs C., Rosenberg P.B., et al. Exercise stimulates Pgc-1alpha transcription in skeletal muscle through activation of the p38 MAPK pathway. J. Biol. Chem. 2005, 280:19587-19593.
174. Hata K., Nishimura R., Ikeda F., Yamashita K., Matsubara T., Nokubi T., et al. Differential roles of Smad1 and p38 kinase in regulation of peroxisome proliferator-activating receptor gamma during bone morphogenetic protein 2-induced adipogenesis. Mol. Biol. Cell 2003, 14:545-555.
175. Zhang H., Schulz T.J., Espinoza D.O., Huang T.L., Emanuelli B., Kristiansen K., et al. Cross talk between insulin and bone morphogenetic protein signaling systems in brown adipogenesis. Mol. Cell. Biol. 2010, 30:4224-4233.
176. Sellayah D., Bharaj P., Sikder D. Orexin is required for brown adipose tissue development, differentiation, and function. Cell Metab. 2011, 14:478-490.
177. Yadav H., Quijano C., Kamaraju A.K., Gavrilova O., Malek R., Chen W., et al. Protection from obesity and diabetes by blockade of TGF-beta/Smad3 signaling. Cell Metab. 2011, 14:67-79.
178. Fournier B., Murray B., Gutzwiller S., Marcaletti S., Marcellin D., Bergling S., et al. Blockade of the activin receptor IIb activates functional brown adipogenesis and thermogenesis by inducing mitochondrial oxidative metabolism. Mol. Cell. Biol. 2012, 32:2871-2879.
179. Yoshida H., Kanamori Y., Asano H., Hashimoto O., Murakami M., Kawada T., et al. Regulation of brown adipogenesis by the Tgf-beta family: involvement of Srebp1c in Tgf-beta- and activin-induced inhibition of adipogenesis. Biochim. Biophys. Acta 2013, 1830:5027-5035.
180. Molchadsky A., Ezra O., Amendola P.G., Krantz D., Kogan-Sakin I., Buganim Y., et al. p53 is required for brown adipogenic differentiation and has a protective role against diet-induced obesity. Cell Death Differ 2013, 20:774-783.
181. McDonald M.E., Li C., Bian H., Smith B.D., Layne M.D., Farmer S.R. Myocardin-related transcription factor A regulates conversion of progenitors to beige adipocytes. Cell 2015, 160:105-118.
182. Qian S.W., Tang Y., Li X., Liu Y., Zhang Y.Y., Huang H.Y., et al. BMP4-mediated brown fat-like changes in white adipose tissue alter glucose and energy homeostasis. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:E798-E807.
183. Kuo M.M., Kim S., Tseng C.Y., Jeon Y.H., Choe S., Lee D.K. BMP-9 as a potent brown adipogenic inducer with anti-obesity capacity. Biomaterials 2014, 35:3172-3179.
184. Hinoi E., Iezaki T., Fujita H., Watanabe T., Odaka Y., Ozaki K., et al. PI3 K/Akt is involved in brown adipogenesis mediated by growth differentiation factor-5 in association with activation of the Smad pathway. Biochem. Biophys. Res. Commun. 2014, 450:255-260.
185. Hinoi E., Nakamura Y., Takada S., Fujita H., Iezaki T., Hashizume S., et al. Growth differentiation factor-5 promotes brown adipogenesis in systemic energy expenditure. Diabetes 2014, 63:162-175.
186. Zhang C., McFarlane C., Lokireddy S., Masuda S., Ge X., Gluckman P.D., et al. Inhibition of myostatin protects against diet-induced obesity by enhancing fatty acid oxidation and promoting a brown adipose phenotype in mice. Diabetologia 2012, 55:183-193.
187. Whittle A.J., Carobbio S., Martins L., Slawik M., Hondares E., Vazquez M.J., et al. BMP8B increases brown adipose tissue thermogenesis through both central and peripheral actions. Cell 2012, 149:871-885.
188. Townsend K.L., Suzuki R., Huang T.L., Jing E., Schulz T.J., Lee K., et al. Bone morphogenetic protein 7 (BMP7) reverses obesity and regulates appetite through a central mTOR pathway. FASEB J. 2012, 26:2187-2196.
189. Townsend K.L., An D., Lynes M.D., Huang T.L., Zhang H., Goodyear L.J., et al. Increased mitochondrial activity in BMP7-treated brown adipocytes, due to increased. Antioxid. Redox Signal. 2013, 19:243-257.
190. Boon M.R., van den Berg S.A., Wang Y., van den Bossche J., Karkampouna S., Bauwens M., et al. BMP7 activates brown adipose tissue and reduces diet-induced obesity only at subthermoneutrality. PLoS One 2013, 8. e74083.